TG Therapeutics, Inc.
(NASDAQ:TGTX) stock is up on Tuesday as the company announced positive topline Phase 1 data for its subcutaneous BRIUMVI (ublituximab-xiiy) for myasthenia gravis (MG), a chronic autoimmune neuromuscular disorder that causes weakness and rapid fatigue in voluntary muscles.
This news comes during a generally positive market environment, with the S&P 500 gaining 0.3% and the Healthcare sector up 0.9%, indicating that TG Therapeutics is moving in line with broader market trends.
Read Also: TG Therapeutics Stock Surges After Drug Trial Update Subcutaneous BRIUMVI Phase 1 Data The Phase 1 study showed that 82% of subjects achieved a minimal clinically important difference (MCID) in their MG-ADL scores, with a mean improvement of over 4 points.
The company plans to initiate a Phase 2 trial that will enroll approximately 120 patients, aiming to combine rapid symptom control with sustained disease modification.
